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Abstract
Oxidative stress, including the reactive oxygen or nitrogen species generated in the enzymat-
ical oxidationor auto-oxidation of an excess amount of dopamine, is thought to play an important
role in dopaminergic neurotoxicity. Dopamine and its metabolites containing 2 hydroxyl residues
exert cytotoxicityin dopaminergic neuronal cells, primarily due to the generation of highly reac-
tive dopamine and DOPA quinones. Dopamine and DOPA quinones may irreversibly alter protein
function through the formation of 5-cysteinyl-catechols on the proteins. Furthermore, the quinone
formation is closely linked to other representative hypotheses such as mitochondrial dysfunction,
inflammation, oxidative stress, and dysfunction of the ubiquitin-proteasome system, in the patho-
genesis of neurodegenerative diseases. Therefore, pathogenic effects of the dopamine quinone
have recently focused on dopaminergicneuron-specific oxidative stress. In this article, we pri-
marily review recent studies on the pathogenicity of quinone formation, in addition to several
neuroprotective approaches against dopaminequinone-induced dysfunction of dopaminergic neu-
rons.
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xidative stress,  including the generation of 
reactive oxygen species (ROS) and reactive 
nitrogen species (RNS) in the oxidation of dopamine 
(DA),  is thought to play a role in dopaminergic neuro-
degeneration in several pathological conditions.
　 It is well known that methamphetamine (METH) 
causes damage to striatal dopaminergic and serotoner-
gic nerve terminals [1ﾝ3].  Various hypotheses 
regarding the mechanism responsible for METH-
induced neurotoxicity has been proposed [4ﾝ15].  
Several studies have demonstrated that endogenous 
dopamine (DA) plays an important role in mediating 
METH-induced neuronal damage [7,  10,  13,  14].  
DA release and redistribution from synaptic vesicles 
to cytoplasmic compartments and consequent elevation 
of cytosolic oxidizable DA concentrations are thought 
to be related to DA terminal injury induced by METH 
exposure [7].  ROS such as superoxide (O2ﾝ) and 
hydroxyl radicals (･OH),  generated by auto-oxidation 
of cytosolic free DA,  appear to be involved in METH-
induced dopaminergic neuronal damage [5].  However,  
the exact mechanism responsible for its striatum-spe-
ciﬁc neurotoxicity remains unclear.
　 In Parkinsonʼs disease,  L-DOPA therapy is a 
standard approach,  as it is designed to replenish the 
loss of DA from dopaminergic neurons.  Despite the 
marked beneﬁts of L-DOPA,  its long-term use may 
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cause adverse eﬀects,  especially motor ﬂuctuations 
such as the wearing-oﬀ phenomenon and dyskinesia,  as 
well as psychiatric symptoms [16,  17].  In advanced 
Parkinsonʼs disease,  L-DOPA does not completely 
replenish DA because few dopaminergic neurons 
remain in the nigrostriatal pathway.  The pathogenic 
eﬀects of L-DOPA and DA have been well docu-
mented.
　 A number of studies have shown that oxidative 
stress,  mitochondrial dysfunction,  inﬂammation,  and 
impairment of the ubiquitin-proteasome system play 
important roles in the METH-induced neurotoxicity 
[6,  18,  19] and the pathogenesis of sporadic and 
familial Parkinsonʼs disease [20ﾝ27].  However,  the 
mechanisms of dopaminergic neuron-speciﬁc cell loss 
have not been fully clariﬁed.  More recently,  an addi-
tional factor,  DA quinone formation,  has been inves-
tigated.  This article focuses on the role of quinone 
formation in neurotoxicity by reviewing studies of 
METH-induced neuronal damage and of L-DOPA-
treated parkinsonian models.  In addition,  neuropro-
tective approaches against DA quinone-induced 
pathogenicity are also addressed.
Dopaminergic Neurotoxicity Related to  
Generation of Free Radicals
　 DA as a neurotransmitter is stable in the synaptic 
vesicle.  However,  when an excess amount of cytosolic 
DA exists outside of the synaptic vesicle in the dam-
aged neurons,  i.e.,  after METH injection or L-DOPA 
treatment using parkinsonian models,  DA is easily 
metabolized via monoamine oxidase (MAO) or by auto-
oxidation to produce cytotoxic ROS,  and then subse-
quent neuromelanin formation [28].  In the oxidation 
of DA by MAO,  H2O2 and dihydroxyphenylacetic acid 
(DOPAC) are generated.  In contrast,  non-enzymatical 
and spontaneous auto-oxidation of DA produces O2ﾝ 
and reactive quinones [29].  Generated O2ﾝ is con-
verted to H2O2 by superoxide dismutase (SOD) and O2ﾝ 
also reacts with nitric oxide radicals (NO･) to conse-
quently generate peroxynitrite (ONOOﾝ) of RNS.  In 
the dopaminergic neurons,  where transition metals are 
abundant,  H2O2 can react with metals,  especially iron,  
to form the most cytotoxic radical,  ･OH.  Therefore,  
it is suggested that L-DOPA- or DA-induced cell death 
is mainly due to ROS generation in the auto-oxidation 
of L-DOPA and/or DA.  Some reports have shown 
that DA or L-DOPA exert either neuroprotective or 
even no eﬀects on ROS generation in some circum-
stances [30ﾝ32].  However,  this excess DA- or 
L-DOPA-induced neurotoxicity mediated by the gen-
eration of free radicals has been reported in damaged 
neurons in many in vitro and in vivo studies [5,  33ﾝ
35].  We have demonstrated that repeated administra-
tion of L-DOPA increases lipid peroxidation in the 
striatum of parkinsonian mice lesioned by intracere-
broventricular injection of 6-OHDA [34].
Dopamine Quinone Formation as a  
Dopaminergic Neuron-speciﬁc  
Pathogenic Factor
　 In contrast to the general oxidative stress induced 
by ROS or RNS,  the pathogenicity of quinone forma-
tion has recently received attention as dopaminergic 
neuron-speciﬁc oxidative stress [24,  35ﾝ38].  As 
mentioned above,  when the DA neurons are damaged,  
an excess amount of cytosolic DA existing outside of 
the synaptic vesicle is spontaneously oxidized and 
produces O2ﾝ and reactive quinones such as DA qui-
nones or DOPA quinones [29,  39].  DA quinones are 
also generated in the enzymatic oxidation of DA by 
cyclooxygenase (COX) as prostaglandin H synthase,  
lipoxygenase,  tyrosinase and xanthine oxidase [29,  
39ﾝ43].  These quinones are easily oxidized to the 
cyclized aminochromes: DA-chrome and DOPA-
chrome,  and then are ﬁnally polymerized to form 
melanin.  Although ROS by the auto-oxidation of DA 
shows widespread toxicity not only in DA neurons but 
also in other regions,  highly reactive DA quinone or 
DOPA quinone itself exerts predominant cytotoxicity 
in DA neurons and surrounding neural cells,  since 
these quinones are generated from free cytosolic DA 
outside the synaptic vesicle.
　 The quinones generated from DA or L-DOPA 
exert cytotoxicity in or beside dopaminergic neurons 
by interacting with various bioactive molecules.  The 
functional proteins that possess cysteine residues are 
thought to be the targets of these catechol quinones.  
The DA quinone and L-DOPA quinone conjugate with 
the sulfhydryl group of the amino acid cysteine,  
resulting predominantly in the formation of 5-cyste-
inyl-DA and 5-cysteinyl-DOPA,  respectively [29,  44,  
45].  The covalent modiﬁcation of cysteine residues by 
DA quinone or DOPA quinone to form 5-cysteinyl-
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catechols (5-cysteinyl-DA,  -DOPA and -DOPAC) 
would irreversibly alter or inhibit protein function and 
consequently cause cytotoxicity,  since the cysteine 
residues are often found at the active sites of func-
tional proteins.  This mechanism of neurotoxicity by 
the formation of 5-cysteinyl-catechols on protein is 
supported by evidence showing the generation of cat-
echol quinones and the consequent formation of 
5-cysteinyl-catechols in DA- and L-DOPA-induced cell 
loss of dopaminergic neuronal cells [46ﾝ48].  In par-
ticular,  it is of interest that DA quinones generated 
in the brain covalently modify and inactivate tyrosine 
hydroxylase,  a DA-synthesizing enzyme to subse-
quently form redox-cycling quinoprotein [49,  50].  
The DA quinones also covalently conjugate with cys-
teine residues in the DA transporter (DAT) to conse-
quently inhibit DA uptake [51].  More interestingly,  
LaVoie et al.  have shown that DA covalently modiﬁes 
parkin protein,  in a gene mutation causing familial 
Parkinsonʼs disease,  to increase parkin insolubility 
and to inactivate its E3 ubiquitin ligase function [38].  
Our previous study showed that the antisense knock-
down of parkin causes apoptotic death of human 
dopaminergic SH-SY5Y cells accompanied by accumu-
lation of DA-chrome generated from DA quinone 
[52].  Therefore,  we suppose that parkin has a proﬁle 
as a DA quinone-quenching molecule to prevent DA 
quinone-induced pathogenicity.  The ｸ-synuclein,  
which is a major component of the insoluble ﬁbrils of 
Lewy bodies in patients with Parkinsonʼs disease,  is 
also one of the target proteins for DA quinone [53].  
The soluble state of ｸ-synuclein is converted to aggre-
gate ﬁbrils via transient formation of pathogenic pro-
toﬁbrils by its oligomerization [54].  Mutant ｸ-synu-
clein (A30P),  which is linked to familial autosomal 
dominant Parkinsonʼs disease,  enhances the rate of 
protoﬁbril formation but inhibits the conversion of 
protoﬁbrils to ﬁbrils,  thereby increasing toxic proto-
ﬁbrils [55].  This,  in turn,  leads to the destruction 
of synaptic vesicular membranes [56].  Conway et al.  
have found that DA quinone or L-DOPA quinone 
reacts with ｸ-synuclein to form a quinoprotein DA 
quinone-ｸ-synuclein adduct by coupling to tyrosine 
residues of ｸ-synuclein and/or by nucleophilic attack 
on lysine residues forming a Schiﬀ base,  to conse-
quently inhibit the conversion of toxic protoﬁbrils to 
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Fig.  1　 Neurotoxicity of quinone formation as a dopaminergic neuron-speciﬁc oxidative stress,  which closely links representative 
hypotheses,  mitochondrial dysfunction,  inﬂammation,  oxidative stress,  and impairment of the ubiquitin-proteasome system in the 
pathogenesis of dopaminergic neurodegeneration.
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ﬁbrils [53],  although ｸ-synuclein does not contain 
cysteine residues [50,  57].  These ﬁndings suggest 
that quinone formation by DA auto-oxidation plays an 
important role as a DA neuron-speciﬁc common toxic 
factor in the neurodegenerative processes by 
DA-related oxidative stress.
　 A number of studies have clariﬁed that the cyto-
toxicity of quinone formation is closely linked not only 
to general oxidative stress but also to other represen-
tative hypotheses of METH neurotoxicity and patho-
genesis in Parkinsonʼs disease,  including mitochon-
drial dysfunction,  inﬂammation and proteasome 
impairment (Fig.  1).  Quinone formation by DA oxi-
dation reduces mitochondrial function and opens the 
mitochondrial permeability transition pores in the 
brain [58].  DHBT-1 (7-(2-aminoethyl)-3, 4-dihydro-5-
hydroxy-2H-1, 4-benzothiazine-3-carboxylic acid),  a 
further oxidation product of 5-cysteinyl-DA,  irre-
versibly inhibits the activity of mitochondrial complex 
I [59].  Prostaglandin H synthase,  which exerts both 
COX activity and peroxidase activity on the arachi-
donic acid cascade,  catalyzes the production of pros-
taglandin G2 from arachidonic acid by its COX activ-
ity,  and then converts prostaglandin G2 to 
prostaglandin H2/E2 by its peroxidase activity.  In the 
presence of DA,  oxidative reaction of DA to form DA 
quinone is coupled with the latter step.  In other 
words,  the DA quinone is generated not only in auto-
oxidation of DA,  but also by the enzymatic oxidation 
of DA by prostaglandin H synthase in a reaction medi-
ated by H2O2 [40].  Recently,  Kuhn et al.  have shown 
that DA quinones activate microglia and induce neuro-
toxic genes in METH-induced toxicity [60].  These 
ﬁndings suggest that DA quinones are closely linked 
to inﬂammation and play an important role in the 
degeneration of DA neurons.  Furthermore,  apoptotic 
and selective dopaminergic cell death with formation 
of ubiquitin and ｸ-synuclein-positive inclusion in vitro 
or in vivo induced by the proteasome inhibitor lacta-
cystin or epoxomicin is suppressed by reducing endog-
enous DA,  and is enhanced by treatment with 
L-DOPA or the monoamine oxidase inhibitor pargy-
line [61,  62].  In a related work,  DA was found to 
induce proteasome inhibition in PC12 cells,  and this 
inhibition was attenuated by glutathione (GSH),  
monoamine oxidase inhibitors,  or a DA uptake inhibi-
tor [63].  In addition,  Zafar et al.  have demonstrated 
that DA quinone has the ability to inhibit proteasomal 
activity [64].  These ﬁndings suggest a possible role 
of proteasome inhibition in the toxicity induced by high 
levels of DA or its quinone in the cytosol.
Involvement of Dopamine Quinone Formation 
in Methamphetamine-induced Neurotoxicity
　 METH-induced neurotoxicity is characterized by a 
long-lasting depletion of striatal DA as well as damage 
to striatal dopaminergic nerve terminals.  Auto-
oxidation of cytosolic free DA and consequent genera-
tion of ROS have been reported to be involved in 
METH-induced neurotoxicity in dopaminergic neurons 
[5ﾝ8,  65].  We have previously demonstrated that 
METH-induced dopaminergic neurotoxicity is regu-
lated by quinone formation-related molecules [66].  
METH exposure dose-dependently induced cell death 
in dopaminergic CATH. a cells.  Levels of quinopro-
tein formation,  which represents generation of DA 
quinones,  also increased in a dose-dependent manner 
with METH treatment,  coinciding with cell toxicity.  
Repeated METH injections have been reported to 
cause dopaminergic terminal loss shown as reduction 
of DAT-positive signals in the striatum of animals.  In 
this study,  we conﬁrmed the reduction of DAT-
positive signals in the striatum of BALB/c mice 1,  3,  
and 14 days after repeated METH injections (4 mg/
kg x 4,  i.p.  with 2 h-intervals).  Quinoprotein levels in 
the striatum were signiﬁcantly increased 3 and 14 
days after the repeated METH injections,  coinciding 
with reduction of DAT signals.  The induction of qui-
none reductase by butylated hydroxyanisol (BHA) 
treatment almost completely prevented METH-induced 
quinone generation,  in parallel with the cell toxicity.  
These ﬁndings conﬁrm that DA quinone formation is 
involved in METH-induced dopaminergic neurotoxic-
ity.  Furthermore,  intracellular DA depletion with 
reserpine or ｸ-methyl-p-tyrosine (ｸ-MT) treatment 
signiﬁcantly prevented the elevation of quinoprotein 
formation induced by METH exposure,  suggesting 
that the reduction of endogenous DA could attenuate 
quinone toxicity.  In fact,  there are several reports 
showing that ｸ-MT prevents the toxic eﬀects of 
METH.  Our present study has provided in vitro and in 
vivo evidence indicating that DA quinone formation by 
auto-oxidation of endogenous DA may play an impor-
tant role in METH-induced neurotoxicity.  Using 
vesicular monoamine transporter (VMAT)-2 knock-out 
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mice,  Fumagalli et al.  [8] showed that disruption of 
VMAT potentiates METH-induced neurotoxicity in 
vivo and pointed a greater contribution of intraneuro-
nal DA redistribution rather than extraneuronal 
overﬂow.  Furthermore,  LaVoie and Hastings [9] 
demonstrated that increased intracellular DA oxida-
tion is associated with METH neurotoxicity by mea-
suring 5-cysteinyl-DA,  a product of DA quinone 
bound to cysteinyl residue on protein,  but not extra-
cellular DA.  These experimental ﬁndings indicate that 
DA quinone formation plays an important role in 
METH-induced neurotoxicity.
Role of Dopamine Quinone Formation in a 
Model of Parkinsonʼs Disease
　 The toxicity of L-DOPA and DA has been well 
documented in many experiments [34,  35,  67ﾝ70],  
since we and others ﬁrst demonstrated that L-DOPA 
itself can become a L-DOPA quinone radical and that 
the repeated administration of L-DOPA increases 
lipid peroxidation in the striatum of parkinsonian mice 
[71,  72].  However,  there is some controversy 
regarding L-DOPA treatment-induced pathogenicity in 
patients with Parkinsonʼs disease [73].  Long-term 
L-DOPA therapy causes several adverse eﬀects only 
in parkinsonian patients and not in pathological condi-
tions other than Parkinsonʼs disease.  Furthermore,  
the ELLDOPA study,  which attempted to clarify 
whether L-DOPA is toxic and accelerates the pro-
gression of Parkinsonʼs disease,  showed that 
L-DOPA-treated patients had an increased rate of 
decline in striatal DA uptake (ｹ-CIT) in SPECT,  
although patients treated with L-DOPA showed less 
clinical deterioration [74].  We previously revealed 
that repeated L-DOPA administration (50 mg/kg/day) 
for 7 days elevated striatal DA turnover (2.7-fold) 
and quinone generation (2.4-fold) speciﬁcally on the 
parkinsonian side,  but not on the control side,  of 
hemi-parkinsonian models [75ﾝ77].  Therefore,  the 
excess amount of cytosolic DA outside of the synaptic 
vesicles after L-DOPA treatment may exert inhibitory 
eﬀects on DA re-uptake function through dysfunction 
of DAT (decline of ｹ-CIT uptake) by quinone genera-
tion,  at least in the damaged dopaminergic nerve ter-
minals.  Furthermore,  we recently revealed that DA 
agonists pergolide and pramipexole possess not only 
ROS/RNS-scavenging activities and GSH-increasing 
eﬀects but also a quenching eﬀect on DA-semiquinone 
radicals generated in vitro [75,  77].  In particular,  
pergolide dramatically prevents repeated L-DOPA 
administration-induced striatal quinone generation 
speciﬁcally on the lesioned side of hemi-parkinsonian 
models [77].  Regarding the speciﬁcity to the dopami-
nergic neuronal system and the clinical eﬃcacy,  DA 
agonists may be the most potential therapeutic 
reagents against DA quinone-induced dysfunction of 
DA uptake.
Neuroprotective Molecules and Drugs against 
Dopamine Quinone Toxicity
　 The intrinsic antioxidative molecules protect brain 
tissue from the DA quinone- or L-DOPA quinone-
induced neurotoxicity.  DA- or L-DOPA-induced for-
mation of these quinones,  the consequent quinone-
induced formation of 5-cysteinyl-catechols on 
functional proteins [29,  44,  45],  and the death of 
dopaminergic cells [46ﾝ48] are markedly prevented by 
the addition of superoxide dismutase (SOD),  GSH,  or 
cysteine,  which competes with the sulfhydryl group of 
cysteine on proteins conjugating with DA or DOPA 
quinones,  but not by the addition of catalase [35,  46,  
47,  50,  69,  71].  We previously revealed the neuro-
toxic properties of DA- and L-DOPA-related com-
pounds in human neuroblastoma SH-SY5Y cells to 
generate DA- or DOPA-semiquinone radicals,  which 
are consequently converted to toxic quinones,  and that 
cell death and the formation of these semiquinone 
radicals induced by DA or L-DOPA are markedly 
prevented by the addition of Cu/Zn-SOD or GSH,  but 
not by the addition of catalase [71].  The SOD can act 
as a superoxide: semiquinone oxidoreductase to pre-
vent quinone formation [78].  Furthermore,  by conju-
gating with DA quinone,  GSH prevents DA quinone 
from binding to the sulfhydryl groups of cysteine on 
proteins,  as described above.  Therefore,  the protec-
tive eﬀects of SOD and GSH against DA- or 
L-DOPA-induced cytotoxicity may be the result of 
these antioxidantsʼ quinone-quenching activities.  The 
involvement of quinone formation in DA- or DOPA-
induced cytotoxicity is also supported by our recent 
study,  in which overexpression of Cu/Zn-SOD pro-
tects SH-SY5Y cells against DA-induced cytotoxicity 
accompanied by an increase in their GSH level [71].  
If DA-related neuronal death is caused by the genera-
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tion of general ROS or RNS,  the cytotoxicity of DA 
would be prevented by antioxidants such as ascorbic 
acid and ｸ-tocopherol.  However,  ascorbic acid and ｸ
-tocopherol have lesser or no eﬀects against 
DA-induced cell death in PC12 cells,  while cell death 
is markedly inhibited by the thiol-containing com-
pounds GSH,  N-acetylcysteine,  and dithiothreitol 
[79].  These ﬁndings suggest that intrinsic thiol mol-
ecules including GSH prevent DA quinone from bind-
ing to the sulfhydryl groups of cysteine on functional 
proteins by their conjugation with DA quinone [35,  
40].  However,  a large amount of GSH or its precur-
sor N-acetylcysteine is required in the peripheral 
administration to maintain an eﬀective concentration 
against quinone toxicity in the brain,  since these small 
peptide drugs are easily broken down before they 
cross the blood-brain barrier.
　 Treatment with BHA,  dimethyl fumarate,  or tert-
butylhydroquinone,  each of which up-regulates the 
activity of NAD(P)H: quinone oxidoreductase (NQO:
DT-diaphorase),  protects against cell death related to 
quinone formation [36,  80ﾝ82].  In particular,  
dimethyl fumarate increases not only the activity of 
NQO: DT-diaphorase but also total intracellular GSH 
and the activities of GSH-S-transferase and GSH 
reductase [82] to reduce the cytotoxicity associated 
with DA quinone formation.  Therefore,  some 
reagents that activate NQO may potentially inhibit DA 
quinone-induced neurotoxicity.  As described above,  
we have shown that pretreatment of dopaminergic 
CATH.a cells with NQO-1 inducer,  BHA,  signiﬁ-
cantly and dose-dependently blocks METH-induced 
elevation of quinoprotein,  and ameliorates METH-
induced cell death [66].
　 Moreover,  other potential therapeutic drugs 
against quinone toxicity are nonsteroidal anti-inﬂam-
matory drugs (NSAIDs) that exert anti-inﬂammatory 
and neuroprotective eﬀects against pathogenesis and 
dopaminergic neurodegeneration in parkinsonian 
patients.  NSAIDs have inhibitory eﬀects against 
prostaglandin H synthase,  which oxidize DA to form 
DA quinone.  The NSAIDs indomethacin and aspirin 
inhibit this prostaglandin H synthase-mediated oxida-
tion of DA [83].  In animal experiments,  several 
NSAIDs have been found to protect against dopami-
nergic cell loss in MPTP-treated parkinsonian models 
[84ﾝ86].  In addition,  the reduction of nigral DA 
neurons by MPTP injection was prevented in COX-2 
knockout mice or by treatment with a COX-2 inhibitor 
[87].  Furthermore,  it is indicated that NSAIDs have 
protective eﬀects against METH-induced dopaminer-
gic cell loss in our reports [88].  Therefore,  NSAIDs 
that may suppress the formation of DA quinones by 
inhibiting prostaglandin H synthase could be eﬀective 
in the treatment of not only Parkinsonʼs disease but 
also METH neurotoxicity,  through their anti-inﬂam-
matory action and their reduction of catechol quinone-
induced cytotoxicity [88,  89].
　 The melanin-synthetic enzyme tyrosinase in the 
brain may rapidly oxidize excess amounts of cytosolic 
DA,  thereby preventing slowly progressive cell dam-
age by auto-oxidation of DA [35].  In our previous 
report,  we demonstrated that tyrosinase inhibition and 
transfection of antisense tyrosinase cDNA markedly 
reduced cell viability,  increased intracellular DA,  and 
enhanced DA-induced cell death in CATH.a cells 
[90],  suggesting that the dysfunction of tyrosinase 
produces cell death by increasing intracellular DA 
levels and the consequent gradual auto-oxidation of DA 
to generate toxic ROS and reactive quinones,  includ-
ing DA quinone.  Furthermore,  we have shown the 
protective eﬀects of tyrosinase against METH-induced 
dopaminergic neurotoxicity in vitro and in vivo [66].  In 
particular,  the reduction of striatal DAT induced by 
the METH injection was dramatically aggravated in 
the tyrosinase-null mice,  which showed higher quino-
protein levels,  compared with that in the wild-type 
mice.  These results suggest that tyrosinase plays a 
protective role against METH-induced dopaminergic 
neurotoxicity in neuronal cells by regulating quinone 
formation.
　 Cysteine-rich metal-binding proteins,  metallothio-
nein (MT)-1 and -2 are considered by some investiga-
tors to have a therapeutic potential based on their 
neuroprotective role [91,  92].  MTs are a family of 
low-molecular weight,  cysteine-rich (30ｵ of the pro-
tein),  ubiquitous,  and inducible intracellular proteins 
that bind to heavy metals such as zinc,  copper,  and 
cadmium,  participating in metal homeostasis and 
detoxiﬁcation [93].  MTs help to regulate metal 
homeostasis in the brain as well as exerting neural 
protective functions in various pathological and inﬂam-
matory conditions [93,  94].  Attention has been 
focused on MTs as radical scavengers because of their 
abundant thiol groups,  which participate exclusively 
in the formation of metal-thiolate clusters [95ﾝ98].  
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Recently,  we have reported that MT quenches DA 
semiquinones in vitro,  and that MT protects against 
DA quinone neurotoxicity in vitro and in vivo [99].
Concluding Remarks
　 In conclusion,  quinone formation by auto-oxidation 
of DA may play an important role as a DA neuron-
speciﬁc common pathogenic and/or degenerative factor 
not only in METH neurotoxicity but also in dysfunc-
tion of dopaminergic neurons of the parkinsonian 
model treated with L-DOPA,  because DA quinone is 
closely linked to oxidative stress,  mitochondrial dys-
function,  inﬂammation,  and proteasome impairment 
(Fig. 1).  Furthermore,  we reviewed some neuropro-
tective molecules and drugs against quinone-induced 
pathogenicity.  Enhancing activities of quenching or 
inhibitory properties against quinone formation would 
provide a novel neuroprotective approach to prevent 
dopaminergic neurodysfunction and/or neurodegenera-
tion.
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